IT202000009370A1 - Composition for use in therapy, in particular for the treatment of overweight, obesity and for the reduction of excess body fat - Google Patents
Composition for use in therapy, in particular for the treatment of overweight, obesity and for the reduction of excess body fat Download PDFInfo
- Publication number
- IT202000009370A1 IT202000009370A1 IT102020000009370A IT202000009370A IT202000009370A1 IT 202000009370 A1 IT202000009370 A1 IT 202000009370A1 IT 102020000009370 A IT102020000009370 A IT 102020000009370A IT 202000009370 A IT202000009370 A IT 202000009370A IT 202000009370 A1 IT202000009370 A1 IT 202000009370A1
- Authority
- IT
- Italy
- Prior art keywords
- weight
- percentage
- total weight
- composition according
- asparagus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 27
- 208000008589 Obesity Diseases 0.000 title claims description 9
- 206010033307 Overweight Diseases 0.000 title claims description 9
- 235000020824 obesity Nutrition 0.000 title claims description 9
- 230000009467 reduction Effects 0.000 title claims description 8
- 238000002560 therapeutic procedure Methods 0.000 title claims description 4
- 210000000577 adipose tissue Anatomy 0.000 title description 3
- 235000005340 Asparagus officinalis Nutrition 0.000 claims description 11
- 235000009108 Urtica dioica Nutrition 0.000 claims description 11
- 241000208140 Acer Species 0.000 claims description 10
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 10
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 10
- 241000219422 Urtica Species 0.000 claims description 10
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 241000220317 Rosa Species 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 235000003642 hunger Nutrition 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010048909 Boredom Diseases 0.000 claims description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 230000036642 wellbeing Effects 0.000 claims description 2
- 241000234427 Asparagus Species 0.000 claims 6
- 244000046151 Acer negundo Species 0.000 claims 1
- 235000004422 Acer negundo Nutrition 0.000 claims 1
- 244000003416 Asparagus officinalis Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 3
- 241000191291 Abies alba Species 0.000 description 1
- 235000004507 Abies alba Nutrition 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241001312519 Trigonella Species 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
CAMPO TECNICO DELL?INVENZIONE TECHNICAL FIELD OF THE INVENTION
La presente invenzione riguarda una nuova composizione, in particolare per l?uso nella terapia di pazienti, pi? in particolare per la cura del sovrappeso, dell?obesit? e per la riduzione del grasso corporeo in eccesso. The present invention relates to a new composition, in particular for use in the therapy of patients, more in particular for the treatment of overweight, obesity? and for the reduction of excess body fat.
STATO DELLA TECNICA ANTERIORE STATE OF THE PRIOR ART
Sono stati proposte molte composizioni per il trattamento del sovrappeso e dell?obesit?. Tuttavia, tali composizioni non riescono ad alleviare in maniera duratura ed efficace il sovrappeso e l?obesit? perch? non agiscono sull?area del cervello coinvolta nella motivazione, nel desiderio e nell?autocontrollo. Many compositions have been proposed for the treatment of overweight and obesity. However, these compositions fail to alleviate overweight and obesity in a lasting and effective way. why? they do not affect the area of the brain involved in motivation, desire and self-control.
Peraltro, le stesse composizioni richiedono costosi procedimenti produttivi che si riflettono negativamente sul prezzo finale del prodotto da somministrare. Moreover, the same compositions require expensive production processes which negatively affect the final price of the product to be administered.
SCOPI DELL?INVENZIONE OBJECTS OF THE INVENTION
Uno scopo della presente invenzione ? quello di fornire una nuova composizione. An object of the present invention ? to provide a new composition.
Un altro scopo della presente invenzione ? quello di fornire una nuova composizione per l?uso nella terapia in pazienti, in particolare per la riduzione del sovrappeso e dell?obesit? e per aumentare la capacit? di autocontrollo nel trattamento o nella cura del sovrappeso e dell?obesit?, per la riduzione del grasso corporeo in eccesso. Another object of the present invention ? is to provide a new composition for use in the therapy of patients, in particular for the reduction of overweight and obesity? and to increase the capacity? of self-control in the treatment or cure of overweight and obesity, for the reduction of excess body fat.
Un altro scopo della presente invenzione ? quello di fornire una composizione come sopra indicato che sia semplice e facile da ottenere. Another object of the present invention ? that of providing a composition as indicated above which is simple and easy to obtain.
Un altro scopo della presente invenzione ? quello di fornire una composizione come sopra indicato che sia economica da realizzare. Another object of the present invention ? that of providing a composition as indicated above which is economical to produce.
Conformemente ad un aspetto della presente invenzione ? prevista una composizione secondo la rivendicazione 1. According to an aspect of the present invention ? provided a composition according to claim 1.
Conformemente ad un altro aspetto della presente invenzione ? prevista una capsula secondo la rivendicazione 9. According to another aspect of the present invention ? provided a capsule according to claim 9.
Conformemente ad un ulteriore aspetto della presente invenzione ? prevista una confezione secondo la rivendicazione 10. According to a further aspect of the present invention ? provided a package according to claim 10.
Le rivendicazioni dipendenti si riferiscono a caratteristiche vantaggiose dell?invenzione. The dependent claims refer to advantageous features of the invention.
ESEMPI DI REALIZZAZIONE DELL?INVENZIONE EXAMPLES OF CARRYING OUT THE INVENTION
La presente invenzione riguarda un preparato o una composizione comprendente i seguenti componenti: The present invention relates to a preparation or composition comprising the following components:
- rosa (Rosa), ad esempio in una percentuale in peso tra 12% e 22% sul peso totale, - acero (Acer), ad esempio in una percentuale in peso tra 9% e 19% sul peso totale, - ortica (Urtica dioica subsp dioica), ad esempio in una percentuale in peso tra 16% e 26% sul peso totale, - rose (Rosa), for example in a percentage by weight between 12% and 22% of the total weight, - maple (Acer), for example in a percentage by weight between 9% and 19% of the total weight, - nettle (Urtica dioica subsp dioica), for example in a percentage by weight between 16% and 26% of the total weight,
- abete (Abies alba), ad esempio in una percentuale in peso tra 8% e 18% sul peso totale, - fieno greco (Trigonella foenum-graecumL.), ad esempio in una percentuale in peso tra 15% e 25% sul peso totale, e - fir (Abies alba), for example in a percentage by weight between 8% and 18% of the total weight, - fenugreek (Trigonella foenum-graecumL.), for example in a percentage by weight between 15% and 25% of the total weight total, e
- asparago (Asparagus officinalis), ad esempio in una percentuale in peso tra 10% e 20% sul peso totale. - asparagus (Asparagus officinalis), for example in a percentage by weight between 10% and 20% of the total weight.
Vantaggiosamente, le percentuali dei suddetti componenti sono come di seguito indicato: - rosa in una percentuale in peso tra 16% e 18% sul peso totale, Advantageously, the percentages of the aforesaid components are as indicated below: - pink in a percentage by weight between 16% and 18% of the total weight,
- acero in una percentuale in peso tra 13% e 15% sul peso totale, - maple in a percentage by weight between 13% and 15% of the total weight,
- ortica in una percentuale in peso tra 20% e 22% sul peso totale, - nettle in a percentage by weight between 20% and 22% of the total weight,
- abete in una percentuale in peso tra 12% e 14% sul peso totale, - fir in a weight percentage between 12% and 14% of the total weight,
- fieno greco in una percentuale in peso tra 19% e 21% sul peso totale, - fenugreek in a percentage by weight between 19% and 21% of the total weight,
- asparago verde in una percentuale in peso tra 14% e 16% sul peso totale. - green asparagus in a weight percentage between 14% and 16% of the total weight.
Una composizione preferita secondo la presente invenzione comprende i suddetti componenti alle percentuali in peso come riportate qui di seguito: A preferred composition according to the present invention comprises the above components at the percentages by weight as indicated below:
- rosa in una percentuale in peso pari a circa il 17% sul peso totale, - pink in a percentage by weight equal to about 17% of the total weight,
- acero in una percentuale in peso pari a circa il 14% sul peso totale, - maple in a weight percentage of about 14% of the total weight,
- ortica in una percentuale in peso pari a circa il 21% sul peso totale, - nettle in a percentage by weight equal to about 21% of the total weight,
- abete in una percentuale in peso pari a circa il 13% sul peso totale, - fir in a weight percentage of about 13% of the total weight,
- fieno greco in una percentuale in peso pari a circa il 20% sul peso totale, - fenugreek in a percentage by weight equal to about 20% of the total weight,
- asparago in una percentuale in peso pari a circa il 15% sul peso totale. - asparagus in a percentage by weight equal to about 15% of the total weight.
Peraltro, almeno uno tra rosa, acero, ortica, abete, fieno greco e asparago ? presente sotto forma di estratto secco. Di preferenza, tutti tali componenti sono presenti sotto forma di estratti secchi. Moreover, at least one of rose, maple, nettle, fir, fenugreek and asparagus? present in the form of dry extract. Preferably, all such components are present in the form of dry extracts.
Se ? presente la rosa, anch?essa ? vantaggiosamente presente sotto forma di estratto secco. Un preparato o una composizione secondo la presente invenzione ? principalmente per l?uso nella terapia del sovrappeso e dell'obesit?, in particolare per la riduzione della massa grassa in eccesso. Self ? present the rose, too? advantageously present in the form of dry extract. A preparation or a composition according to the present invention ? mainly for use in the treatment of overweight and obesity, in particular for the reduction of excess fat mass.
Peraltro, una composizione in accordo con la presente invenzione pu? essere somministrata in capsule, ad esempio in capsule ciascuna di peso tra circa 0,4 e circa 0,6 g, volendo circa 0,5 g. Moreover, a composition in accordance with the present invention can be administered in capsules, for example in capsules each weighing between about 0.4 and about 0.6 g, preferably about 0.5 g.
In merito a ci?, una confezione potrebbe comprende tra 200 e 300 capsule, ad esempio 240 capsule. In this regard, a package could contain between 200 and 300 capsules, for example 240 capsules.
Per l?ottenimento di una composizione secondo la presente invenzione, si possono ad esempio essiccare le foglie dei componenti sopra indicati, dopodich? si polverizzano le foglie essiccate in modo da ottenere un preparato di consistenza polverosa con granulometria omogenea fine. Per l?incapsulamento della composizione si pu? invece seguire un procedimento standard. La composizione secondo la presente invenzione, in particolare sotto forma di capsule ? stata somministrata, nell?arco di un anno, ad una serie di pazienti, chiaramente umani, e si ? avuto modo di riscontrare che dopo quattro settimane continue di somministrazione si verificava una riduzione di massa grassa, la riduzione del sovrappeso e dell?obesit? e l'aumento della capacit? di autocontrollo nella gestione della fame nervosa nei pazienti umani che avevano un?alterazione del meccanismo di controllo da parte dell?ipotalamo. To obtain a composition according to the present invention, the leaves of the components indicated above can be dried, for example, after which they are dried. the dried leaves are pulverized in order to obtain a powdery consistency preparation with a fine homogeneous granulometry. For the encapsulation of the composition you can? instead follow a standard procedure. The composition according to the present invention, in particular in the form of capsules, is been administered, within a year, to a series of patients, clearly human, and yes ? was able to find that after four weeks of continuous administration there was a reduction in fat mass, the reduction of overweight and obesity? and the increase in capacity? of self-control in the management of nervous hunger in human patients who had an alteration of the control mechanism by the hypothalamus.
In particolare, si ? avuto modo di notare una netta diminuzione degli episodi di fame nervosa per noia, per ansia, per tristezza, scarsa autostima e solitudine. I pazienti sottoposti al trattamento miglioravano il sonno, le manifestazioni affettive e il senso di benessere in generale. In particular, yes? had the opportunity to notice a clear decrease in episodes of nervous hunger due to boredom, anxiety, sadness, low self-esteem and loneliness. Patients undergoing the treatment improved sleep, affective manifestations, and general sense of well-being.
In generale, la somministrazione di una composizione secondo la presente invenzione migliorava lo stato di forma fisica dei rispettivi pazienti. In general, the administration of a composition according to the present invention improved the fitness status of the respective patients.
Il trattamento ? stato condotto in particolare somministrando da 2 a 4 capsule al mattino, da 2 a 4 a pranzo e da 3 a 5 la sera. The treatment ? was conducted in particular by administering 2 to 4 capsules in the morning, 2 to 4 at lunch and 3 to 5 in the evening.
Modifiche e varianti dell?invenzione sono possibili entro l?ambito di protezione definito dalle rivendicazioni. Modifications and variations of the invention are possible within the scope of protection defined by the claims.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000009370A IT202000009370A1 (en) | 2020-04-29 | 2020-04-29 | Composition for use in therapy, in particular for the treatment of overweight, obesity and for the reduction of excess body fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000009370A IT202000009370A1 (en) | 2020-04-29 | 2020-04-29 | Composition for use in therapy, in particular for the treatment of overweight, obesity and for the reduction of excess body fat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT202000009370A1 true IT202000009370A1 (en) | 2021-10-29 |
Family
ID=72644543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102020000009370A IT202000009370A1 (en) | 2020-04-29 | 2020-04-29 | Composition for use in therapy, in particular for the treatment of overweight, obesity and for the reduction of excess body fat |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT202000009370A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10029562A1 (en) * | 1999-06-24 | 2001-03-01 | Strathmann Ag & Co | Medicament useful for treating immunological disorders, Alzheimer's disease, diabetes and obesity comprises a nettle extract prepared using an extractant other than water, ethanol and their mixtures |
| US20060159724A1 (en) * | 2000-08-08 | 2006-07-20 | Bell Stacey J | Nutritional supplement for the management of weight |
| CN103468493A (en) * | 2013-08-12 | 2013-12-25 | 杨如义 | Sunflower seed and oat syrup |
| CN103877204A (en) * | 2014-04-19 | 2014-06-25 | 陈晓霞 | Chinese traditional medicine oral liquid for treating obesity and preparation method of oral liquid |
| KR20150057333A (en) * | 2013-11-19 | 2015-05-28 | (주)아모레퍼시픽 | Composition comprising extract of korean fir for preventing and improving obesity |
-
2020
- 2020-04-29 IT IT102020000009370A patent/IT202000009370A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10029562A1 (en) * | 1999-06-24 | 2001-03-01 | Strathmann Ag & Co | Medicament useful for treating immunological disorders, Alzheimer's disease, diabetes and obesity comprises a nettle extract prepared using an extractant other than water, ethanol and their mixtures |
| US20060159724A1 (en) * | 2000-08-08 | 2006-07-20 | Bell Stacey J | Nutritional supplement for the management of weight |
| CN103468493A (en) * | 2013-08-12 | 2013-12-25 | 杨如义 | Sunflower seed and oat syrup |
| KR20150057333A (en) * | 2013-11-19 | 2015-05-28 | (주)아모레퍼시픽 | Composition comprising extract of korean fir for preventing and improving obesity |
| CN103877204A (en) * | 2014-04-19 | 2014-06-25 | 陈晓霞 | Chinese traditional medicine oral liquid for treating obesity and preparation method of oral liquid |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE WPI Week 201429, Derwent World Patents Index; AN 2014-D49830, XP002800814 * |
| DATABASE WPI Week 201457, Derwent World Patents Index; AN 2014-Q59616, XP002800813 * |
| DATABASE WPI Week 201552, Derwent World Patents Index; AN 2015-323792, XP002800816 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190461T1 (en) | Solid composition comprising iron for use in iron deficient conditions | |
| CN101780229B (en) | Traditional Chinese medicine composition for treating gum bleeding and preparation method thereof | |
| JP2012236834A5 (en) | ||
| Al Eid | Efficacy of Commiphora myrrh mouthwash on early wound healing after tooth extraction: A randomized controlled trial | |
| CA3025114A1 (en) | Perilla extract composition | |
| Amit et al. | Formulation and evaluation of a novel herbal gel of Equisetum arvense extract | |
| KR101291338B1 (en) | Use of lavender oil for the prophylaxis and treatment of neuro asthenia, somatization disorders and other diseases associated with stress | |
| IT202000009370A1 (en) | Composition for use in therapy, in particular for the treatment of overweight, obesity and for the reduction of excess body fat | |
| Bozzini et al. | Biomechanical properties of the mandible, as assessed by bending test, in rats fed a low-quality protein | |
| CN101829315B (en) | Traditional Chinese medicine composition for treating headache during menstruation and preparation method thereof | |
| Stoia et al. | Selected evidence-based health benefits of topically applied sunflower oil | |
| CN101310733B (en) | A pharmaceutical composition for treating cardiovascular diseases, and its preparation method | |
| CN103566258A (en) | Traditional Chinese medicine lotion for treating cutaneous pruritus | |
| Dennis et al. | Expression of SP and ALP following the application of watermelon frost in reversible pulpitis: an in vivo study | |
| IT202000004123A1 (en) | COMPOSITION FOR USE IN THERAPY, ESPECIALLY FOR THE TREATMENT OF DEPRESSION | |
| CN103623316A (en) | Traditional Chinese medicine composition for treating alopecia and preparation method thereof | |
| CN103933290B (en) | Chinese medicine composition for the treatment of craniocerebral injury syndrome and preparation method thereof | |
| CN104258097A (en) | Anti-inflammatory and analgesic balm | |
| CN103142911B (en) | Chinese medicine composition for treating alopecia and preparation method thereof | |
| CN106511447A (en) | Nutrition complementing method for repairing cell disorder and medicine recipe for same | |
| CN103239543B (en) | Chinese medicine effective part composition for treating gastroptosis and preparation method of Chinese medicine effective part composition | |
| Sahare et al. | Formulation and Evaluation of Polyherbal Face Pack for Healthy Skin | |
| CN106727642A (en) | A kind of children's antipyretic | |
| Zeng et al. | Linarin attenuates oxaliplatin-induced neuropathic pain by inhibiting NF-κB/NLRP3 signaling pathway | |
| DE102015002709A1 (en) | New use of acetylsalicylic acid and a derivative thereof |